18F-FDG Dedicated Breast PET Complementary to Breast MRI for Evaluating Early Response to Neoadjuvant Chemotherapy.

IF 5.6 Q1 ONCOLOGY Radiology. Imaging cancer Pub Date : 2024-03-01 DOI:10.1148/rycan.230082
Devan Diwanji, Natsuko Onishi, Deep K Hathi, Courtney Lawhn-Heath, John Kornak, Wen Li, Ruby Guo, Julissa Molina-Vega, Youngho Seo, Robert R Flavell, Diane Heditsian, Susie Brain, Laura J Esserman, Bonnie N Joe, Nola M Hylton, Ella F Jones, Kimberly M Ray
{"title":"<sup>18</sup>F-FDG Dedicated Breast PET Complementary to Breast MRI for Evaluating Early Response to Neoadjuvant Chemotherapy.","authors":"Devan Diwanji, Natsuko Onishi, Deep K Hathi, Courtney Lawhn-Heath, John Kornak, Wen Li, Ruby Guo, Julissa Molina-Vega, Youngho Seo, Robert R Flavell, Diane Heditsian, Susie Brain, Laura J Esserman, Bonnie N Joe, Nola M Hylton, Ella F Jones, Kimberly M Ray","doi":"10.1148/rycan.230082","DOIUrl":null,"url":null,"abstract":"<p><p>Purpose To compare quantitative measures of tumor metabolism and perfusion using fluorine 18 (<sup>18</sup>F) fluorodeoxyglucose (FDG) dedicated breast PET (dbPET) and breast dynamic contrast-enhanced (DCE) MRI during early treatment with neoadjuvant chemotherapy (NAC). Materials and Methods Prospectively collected DCE MRI and <sup>18</sup>F-FDG dbPET examinations were analyzed at baseline (T0) and after 3 weeks (T1) of NAC in 20 participants with 22 invasive breast cancers. FDG dbPET-derived standardized uptake value (SUV), metabolic tumor volume, and total lesion glycolysis (TLG) and MRI-derived percent enhancement (PE), signal enhancement ratio (SER), and functional tumor volume (FTV) were calculated at both time points. Differences between FDG dbPET and MRI parameters were evaluated after stratifying by receptor status, Ki-67 index, and residual cancer burden. Parameters were compared using Wilcoxon signed rank and Mann-Whitney <i>U</i> tests. Results High Ki-67 tumors had higher baseline SUV<sub>mean</sub> (difference, 5.1; <i>P</i> = .01) and SUV<sub>peak</sub> (difference, 5.5; <i>P</i> = .04). At T1, decreases were observed in FDG dbPET measures (pseudo-median difference T0 minus T1 value [95% CI]) of SUV<sub>max</sub> (-6.2 [-10.2, -2.6]; <i>P</i> < .001), SUV<sub>mean</sub> (-2.6 [-4.9, -1.3]; <i>P</i> < .001), SUV<sub>peak</sub> (-4.2 [-6.9, -2.3]; <i>P</i> < .001), and TLG (-29.1 mL<sup>3</sup> [-71.4, -6.8]; <i>P</i> = .005) and MRI measures of SER<sub>peak</sub> (-1.0 [-1.3, -0.2]; <i>P</i> = .02) and FTV (-11.6 mL<sup>3</sup> [-22.2, -1.7]; <i>P</i> = .009). Relative to nonresponsive tumors, responsive tumors showed a difference (95% CI) in percent change in SUV<sub>max</sub> of -34.3% (-55.9%, 1.5%; <i>P</i> = .06) and in PE<sub>peak</sub> of -42.4% (95% CI: -110.5%, 8.5%; <i>P</i> = .08). Conclusion <sup>18</sup>F-FDG dbPET was sensitive to early changes during NAC and provided complementary information to DCE MRI that may be useful for treatment response evaluation. <b>Keywords:</b> Breast, PET, Dynamic Contrast-enhanced MRI Clinical trial registration no. NCT01042379 <i>Supplemental material is available for this article.</i> © RSNA, 2024.</p>","PeriodicalId":20786,"journal":{"name":"Radiology. Imaging cancer","volume":null,"pages":null},"PeriodicalIF":5.6000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988337/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiology. Imaging cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1148/rycan.230082","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose To compare quantitative measures of tumor metabolism and perfusion using fluorine 18 (18F) fluorodeoxyglucose (FDG) dedicated breast PET (dbPET) and breast dynamic contrast-enhanced (DCE) MRI during early treatment with neoadjuvant chemotherapy (NAC). Materials and Methods Prospectively collected DCE MRI and 18F-FDG dbPET examinations were analyzed at baseline (T0) and after 3 weeks (T1) of NAC in 20 participants with 22 invasive breast cancers. FDG dbPET-derived standardized uptake value (SUV), metabolic tumor volume, and total lesion glycolysis (TLG) and MRI-derived percent enhancement (PE), signal enhancement ratio (SER), and functional tumor volume (FTV) were calculated at both time points. Differences between FDG dbPET and MRI parameters were evaluated after stratifying by receptor status, Ki-67 index, and residual cancer burden. Parameters were compared using Wilcoxon signed rank and Mann-Whitney U tests. Results High Ki-67 tumors had higher baseline SUVmean (difference, 5.1; P = .01) and SUVpeak (difference, 5.5; P = .04). At T1, decreases were observed in FDG dbPET measures (pseudo-median difference T0 minus T1 value [95% CI]) of SUVmax (-6.2 [-10.2, -2.6]; P < .001), SUVmean (-2.6 [-4.9, -1.3]; P < .001), SUVpeak (-4.2 [-6.9, -2.3]; P < .001), and TLG (-29.1 mL3 [-71.4, -6.8]; P = .005) and MRI measures of SERpeak (-1.0 [-1.3, -0.2]; P = .02) and FTV (-11.6 mL3 [-22.2, -1.7]; P = .009). Relative to nonresponsive tumors, responsive tumors showed a difference (95% CI) in percent change in SUVmax of -34.3% (-55.9%, 1.5%; P = .06) and in PEpeak of -42.4% (95% CI: -110.5%, 8.5%; P = .08). Conclusion 18F-FDG dbPET was sensitive to early changes during NAC and provided complementary information to DCE MRI that may be useful for treatment response evaluation. Keywords: Breast, PET, Dynamic Contrast-enhanced MRI Clinical trial registration no. NCT01042379 Supplemental material is available for this article. © RSNA, 2024.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
18F-FDG 专用乳腺 PET 与乳腺 MRI 相辅相成,用于评估新辅助化疗的早期反应。
目的 比较新辅助化疗(NAC)早期治疗期间使用氟18(18F)脱氧葡萄糖(FDG)专用乳腺PET(dbPET)和乳腺动态对比增强(DCE)MRI对肿瘤代谢和灌注进行的定量测量。材料与方法 对 20 名患有 22 例浸润性乳腺癌的患者在基线(T0)和接受新辅助化疗 3 周后(T1)进行的前瞻性 DCE MRI 和 18F-FDG dbPET 检查进行分析。在这两个时间点计算了 FDG dbPET 导出的标准化摄取值 (SUV)、代谢肿瘤体积和总病变糖酵解 (TLG),以及 MRI 导出的增强百分比 (PE)、信号增强比 (SER) 和功能性肿瘤体积 (FTV)。根据受体状态、Ki-67 指数和残留癌负荷进行分层后,评估 FDG dbPET 和 MRI 参数之间的差异。参数比较采用 Wilcoxon 符号秩检验和 Mann-Whitney U 检验。结果 高 Ki-67 肿瘤的基线 SUVmean 值(差异为 5.1;P = .01)和 SUVpeak 值(差异为 5.5;P = .04)较高。在 T1 期,观察到 FDG dbPET 测量值(伪中位数差异 T0 减 T1 值 [95% CI])SUVmax(-6.2 [-10.2, -2.6]; P < .001)、SUVmean(-2.6 [-4.9, -1.3]; P < .001), SUVpeak (-4.2 [-6.9, -2.3]; P < .001), and TLG (-29.1 mL3 [-71.4, -6.8]; P = .005) and MRI measures of SERpeak (-1.0 [-1.3, -0.2]; P = .02) and FTV (-11.6 mL3 [-22.2, -1.7]; P = .009)。与非反应性肿瘤相比,反应性肿瘤的 SUVmax 百分比变化差异(95% CI)为-34.3%(-55.9%,1.5%;P = .06),PEpeak 百分比变化差异为-42.4%(95% CI:-110.5%,8.5%;P = .08)。结论 18F-FDG dbPET 对 NAC 期间的早期变化很敏感,并能提供 DCE MRI 的补充信息,可能对治疗反应评估有用。关键词乳腺 正电子发射 动态对比增强磁共振成像 临床试验注册号本文有补充材料。© RSNA, 2024.
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.00
自引率
2.30%
发文量
0
期刊最新文献
Multifrequency MR Elastography for Tumor Stiffness Outperforms Conventional Imaging and Clinical Variables in Determining Lymphovascular Space Invasion in Endometrial Cancer. Assessing the Value of 68Ga-FAPI PET/CT in Gastric Mucinous Adenocarcinoma or Signet Ring Cell Carcinoma. External Validation of a Previously Developed Deep Learning-based Prostate Lesion Detection Algorithm on Paired External and In-House Biparametric MRI Scans. Mathematical 3D Liver Model for Surgical versus Ablative Therapy Treatment Planning for Colorectal Liver Metastases: Recommendations from the COLLISION and COLDFIRE Trial Expert Panels. A New Acquisition Protocol for Optimized Dynamic Susceptibility Perfusion Imaging of Brain Tumors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1